Ultimovacs

Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Uncovering Trusts – abrdn UK Smaller Companies Growth Trust (AUSC) – Delving into the trust’s triple discount

Utilico Emerging Markets Trust in 60 seconds

IP Group – executive interview

About Edison

About Edison

Careers

Ultimovacs (OSE: ULTI)

Latest Insights

Ultimovacs — Steadfast commitment to UV1 progression

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Ultimovacs – executive interview

Sector

Research

Ultimovacs – executive interview

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM

Ultimovacs — TENDU results support TET platform expansion

Ultimovacs — Line of sight on INITIUM top-line readout

Ultimovacs — Overall survival is the name of the NIPU PII game

Ultimovacs — Two for two in melanoma Phase I trial

Ultimovacs — UV1 ODD a sign of positive things to come

Ultimovacs — Gearing up for UV1 Phase II trial readouts

Ultimovacs — FOCUS – first in series of upcoming catalysts

Ultimovacs — Positive Phase I update in malignant melanoma

Ultimovacs — UV1 by no means out after NIPU readout

Ultimovacs — All steady as Phase II trial readouts approach

Ultimovacs — NIPU and INITIUM readouts incoming for UV1

Ultimovacs — Gathering steam with multiple inflections in FY23

Ultimovacs — Phase II milestone as licensing potential nears

Ultimovacs — Slight adjustment but trial continues as planned

Ultimovacs — Prostate cancer trial patient enrolment complete

Ultimovacs — On track for upcoming UV1 catalysts

Ultimovacs — First patient in Phase II LUNGVAC study

Ultimovacs – executive interview

Ultimovacs — Biomarker insight into UV1 combination

Ultimovacs – executive interview

Ultimovacs — UV1 encouraging three-year survival data

Ultimovacs — Further positivity for UV1

Ultimovacs — UV1 development funded past key readouts

Ultimovacs — Patient expansion in Phase I TENDU

Ultimovacs — Positive Phase I survival data in melanoma

Ultimovacs — Patient enrolment continues; catalysts approach

Ultimovacs — UV1 Phase II data flow creeps closer

Ultimovacs – executive interview

Ultimovacs – executive interview Test

Ultimovacs — New large indication for UV1

Ultimovacs — Data continue to impress in Phase I UV1 study

Ultimovacs — ORR impressive in Phase I UV1 plus Keytruda

Ultimovacs — Cancer vaccine with virtually universal potential

Ultimovacs – Edison Open House interview

Ultimovacs — Phase II data from 500+ patients over 2022/23

Ultimovacs — Cancer vaccine with near-universal potential